TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03916913

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local radiation therapy
Description: Local radiotherapy on all sites of disease including primary and metastatic lesions
Study: NCT03751917

Intervention type: DRUG
Intervention: Arsenic Trioxide
Description: This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
Study: NCT05419778

Intervention type: DEVICE
Intervention: Osteogen plug®
Description: A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)

Intervention type: DEVICE
Intervention: MInerOss®
Description: A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
Study: NCT01421615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal capsules of lactobacilli
Description: The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal capsules of lactobacilli
Description: The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal capsules of lactobacilli
Description: The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal capsules of lactobacilli
Description: The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal capsules of lactobacilli
Description: The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
Study: NCT02912689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilator Assist
Description: NAVA during Non-invasive ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support ventilation
Description: PS during Non-invasive ventilation
Study: NCT02290249

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Manikin was intubated by different novice personal with glidescope videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Manikin was intubated by different novice personal with glidescope videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Manikin was intubated by different novice personal with glidescope videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: Pediatric manikin was intubated by novice personal with airtraq

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: Pediatric manikin was intubated by novice personal with airtraq

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: Pediatric manikin was intubated by novice personal with airtraq
Study: NCT02170103

Intervention type: PROCEDURE
Group type: OTHER
Intervention: percutaneous intervention (PCI)
Description: Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous intervention (PCI)
Description: Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbubbles
Description: The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Intermittent high Mechanical Index (MI) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MegaHertz (MHz); pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
Study: NCT02062840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity whole-body infrared heating
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low intensity whole-body infrared heating
Description: Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)
Description: A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)
Description: A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Description: Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
Study: NCT02222948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatelizumab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Vatelizumab)
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03619720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Records
Description: Respiratory records, Vocal records Video records Questionnaires
Study: NCT02661334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Flour
Description: rice flour powder matched for color, appearance, taste, and solubility

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Flour
Description: rice flour powder matched for color, appearance, taste, and solubility

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Flour
Description: rice flour powder matched for color, appearance, taste, and solubility

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice Flour
Description: rice flour powder matched for color, appearance, taste, and solubility
Study: NCT03488017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular Coil
Description: Non-invasive ocular device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular Coil
Description: Non-invasive ocular device
Study: NCT02945488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary plan
Description: Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary plan
Description: Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
Study: NCT02403648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-961
Description: BIOD-961 is a lyophilized glucagon formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-961
Description: BIOD-961 is a lyophilized glucagon formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lilly Glucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lilly Glucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novo Glucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novo Glucagon
Study: NCT02096640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type of surgical teqnique for tracheostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type of surgical teqnique for tracheostomy
Study: NCT01130480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Integra Glucometer
Study: NCT04514653

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab (anti-VEGF agent)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 1
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 2
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 3
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 3
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 3
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Steroid
Description: Local steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Steroid
Description: Topical steroid
Study: NCT03551561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSAAC
Description: Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSAAC
Description: Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSAC
Description: Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSAC
Description: Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
Study: NCT03943654

Intervention type: OTHER
Intervention: MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone
Description: The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.

Intervention type: OTHER
Intervention: MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone
Description: The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.

Intervention type: OTHER
Intervention: MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone
Description: The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
Study: NCT00406484

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard drug counseling
Description: Individual drug counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BDRC
Description: Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
Study: NCT02886455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This a newly developed adhesive strip.
Study: NCT03083834

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cosyntropin stimulation test
Description: At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cosyntropin stimulation test
Description: At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cosyntropin stimulation test
Description: At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
Study: NCT02426203

Intervention type: PROCEDURE
Intervention: Pulmonary endarterectomy
Description: Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
Study: NCT01077076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zegerid
Description: Zegerid taken once daily for 11 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilosec OTC™ Tablets
Description: Prilosec OTC™ Tablets taken once daily for 11 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once daily for 11 days.
Study: NCT01342159

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
Study: NCT04782479

Intervention type: PROCEDURE
Intervention: hand position
Description: For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.

Intervention type: PROCEDURE
Intervention: hand position
Description: For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.